Adamis Pharma recalls Symjepi allergy treatment for potential manufacturing defect

  • Adamis Pharmaceuticals Corporation ADMP is voluntarily recalling certain lots of Symjepi (epinephrine) Injection 0.15 mg and 0.3 mg single dose pre-filled syringes at the consumer level.
  • Lots are being recalled due to potential needle clogging preventing epinephrine delivery.
  • US WorldMeds (USWM) exclusively markets and distributes Symjepi in the United States, under license from Adamis.
  • The USWM will manage the entire recall process under the supervision of Adamis.
  • Although not confirmed to be related to the recall, there have been two different customer complaints out of three syringes regarding the difficulty in dispensing the product to date.
  • However, neither US WorldMeds nor Adamis Pharmaceuticals has received or is aware of any adverse events related to this recall.
  • Symjepi is indicated for the emergency treatment of allergic (Type I) reactions, including anaphylaxis.
  • The products are packaged in pre-filled single-dose syringes of 2 units per carton.
  • Price action: ADMP shares were up 0.03% at $0.64 in the premarket session for the last check on Tuesday.

Comments are closed.